Skip to main content Skip to search Skip to main navigation

EC: IVDR for In-vitro-Diagnostic Medical Devices Entered into Force

After a one-year postponement period, the European In Vitro Diagnostic Medical Devices Regulation (IVDR) finally came into force on 26 May 2022 and follows the Medical Device Regulation (MDR), which has been in force for one year.

Thus, these medical device directives valid until that date will cease to apply:

  • Directive on Active Implantable Medical Devices 90/385/EEC (AIMD)
  • Directive on Medical Devices 93/42/EEC (MDD)
  • Directive on in vitro diagnostic medical devices 98/79/EC (IVDD).


With the entry into force of the IVDR, the dates for transition periods have been partially adjusted:

25 May 2022-26 May 2025
Certificates still issued under the IVDD can remain valid until 26 May 2025; however, all Class D devices placed on the market after 26 May 2025 must be fully compliant with the IVDR.

By 26 May 2026
All Class C devices placed on the market after 26 May 2026 must be fully compliant with the IVDR.

26 May 2027
All class B devices and class A sterile devices placed on the market after 26 May 2027 must be fully compliant with the IVDR.

Continued without change from 26 May 2022
All non-sterile class A devices placed on the market after 25 May 2022 must be fully compliant with the IVDR. All new devices placed on the market must comply with the IVDR.


Source:
EC: In Vitro Diagnostic Medical Devices Regulation (IVDR)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What are the General Requirements for Standard Documents?

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
EDQM: Revised Guidance on Sister File Applications

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic has revised its guidance document “Mobile technologies” and added two new entries to the related questions and answers. The update follows an increasing number of queries regarding the details and placement of URLs, the positioning of QR codes and their captions.
Read more
EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA reported that Scholar Rock Netherlands withdrew its application for Isembyld after evaluation had progressed through the final round of questions. EMA’s provisional view was that the medicine could not be authorised because the applicant had not provided confirmation that the manufacturing site complied with EU GMP requirements.

Read more
France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

The French medicines agency ANSM has published an update on its “Longue vie aux médicaments” pilot project aimed at extending the shelf life of medicines. Fourteen pharmaceutical companies responded to the call for applications. The project covers a total of 73 medicines, including commonly used products containing paracetamol, levothyroxine, melatonin or lithium.
Read more
Previous
Next